Print  |  Close

Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial


Active: Yes
Cancer Type: Breast Cancer
Unknown Primary
NCT ID: NCT04852887
Trial Phases: Phase III Protocol IDs: NRG-BR007 (primary)
NRG-BR007
NCI-2021-00222
Eligibility: 50 - 70 Years, Male and Female Study Type: Treatment
Study Sponsor: NRG Oncology
NCI Full Details: http://clinicaltrials.gov/show/NCT04852887

Summary

This phase III trial compares the effect of radiation therapy combined with hormonal therapy versus hormonal therapy alone in treating patients with low risk, early stage breast cancer with Oncotype Dx Recurrence =< 18. Oncotype DX is a laboratory test which results in a score that is used to help predict whether breast cancer will spread to other parts of the body or come back. Radiation therapy uses high doses of radiation to kill cancer cells and shrink tumors but may result in some side effects. Hormones called estrogen and progesterone may contribute to the growth of breast tumor cells. Hormone therapy, also called endocrine therapy, may stop the growth of tumor cells by blocking or removing these hormones. This clinical trial may help researchers understand if patients with low-risk, early stage breast cancer who have Oncotype recurrence score of =< 18 can safely omit radiation therapy and only be treated with hormonal therapy without losing any radiation treatment benefit.

Objectives

PRIMARY OBJECTIVE:
I. To evaluate whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.

SECONDARY OBJECTIVES:
I. To evaluate whether breast conservation surgery and endocrine therapy inclusive of any second breast conservation surgery for salvage of IBTR results in a non-inferior rate of overall breast conservation compared to breast conserving surgery, endocrine therapy, and radiation for IBTR.
II. To evaluate whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive ipsilateral breast tumor recurrence (IIBTR) compared to breast conservation, breast radiation, and endocrine therapy.
III. To evaluate whether breast conservation surgery and endocrine therapy results in a non-inferior relapse free interval (RFI) compared to breast conservation, breast radiation, and endocrine therapy.
IV. To evaluate whether breast conservation surgery and endocrine therapy results in a non-inferior distant disease-free survival (DDFS) compared to breast conservation, breast radiation, and endocrine therapy.
V. To evaluate whether breast conservation surgery and endocrine therapy results in a non-inferior overall survival (OS) compared to breast conservation, breast radiation, and endocrine therapy.
VI. To evaluate whether there is a difference in patient-reported breast pain in women who do and do not receive breast radiation.
VII. To evaluate whether there is a difference in patient-reported worry about recurrence in women who do and do not receive breast radiation.
VIII. To evaluate whether adherence to endocrine therapy following breast conservation surgery alone is non inferior compared to endocrine therapy with breast conservation surgery and breast radiation.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Within 12 weeks of the last breast cancer surgery, patients undergo external beam radiation therapy. Patients also receive endocrine therapy for a minimum of 5 years initiated before, during, or after completion of radiation therapy at the discretion of the investigator. Endocrine therapy may include tamoxifen, anastrozole, letrozole, exemestane, or luteinizing hormone-releasing hormone (LHRH) agonist/antagonist. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo mammogram or magnetic resonance imaging (MRI) as well as optional blood sample collection throughout the trial.

ARM II: Patients receive endocrine therapy for a minimum of 5 years at the discretion of the investigator. Endocrine therapy may include tamoxifen, anastrozole, letrozole, exemestane, or LHRH agonist/antagonist. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo mammogram or MRI as well as optional blood sample collection throughout the trial.

After completion of study treatment, patients are followed up every 6 months for 24 months, and then every 12 months from year 3 through year 10 after randomization.

Treatment Sites in Georgia

Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
225 Candler Drive
Savannah, GA 31405
912-819-5778
www.sjchs.org



Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.